Advisory board will contribute to driving innovation and technology aligned with company strategic priorities
Inaugural board participants include established pharma & biotech executives, academics
NOTTINGHAM, UK; July 15, 2025–Quotient Sciences, a leading integrated CRDMO (contract research, development and manufacturing organization) for the pharmaceutical and biotech industry, is pleased to announce the formation of its Scientific Advisory Board (SAB) and appointment of inaugural members from the US, UK and Europe.
The Quotient Sciences SAB was formed to enhance the Company’s commitment to scientific innovation and excellence in drug development, with members providing a diverse range of views and specialisms.
The SAB will work closely with Quotient Sciences' scientific and executive leadership to provide input on research and development priorities, technology investments, and scientific strategy.
The founding board members are distinguished leaders from pharma, biotech, and academia with decades of experience in drug development, pharmaceutical manufacturing and drug delivery technologies. They are:
Dr. Dominique Demolle, CEO of Cognivia: Dr. Demolle has held leadership roles at Eli Lilly, including Associate Director of Global Early Phase Operations. She co-founded Cognivia in 2013, leveraging machine learning and patient psychology to enhance clinical trials. Dr. Demolle was honored as one of the Most Inspiring People in Life Sciences by the 2022 PharmaVoice 100 awards. She earned her Ph.D. in Biochemistry from the University of Brussels.
Dr. Alastair Coupe, Independent CMC Consultant: Dr. Coupe brings deep expertise in drug development, regulatory strategy, and pediatric formulation from over 30 years of experience across senior scientific roles at Pfizer and 3M Health Care. Notably, he directed the cross-industry Innovate UK project focused on accelerating pediatric drug development, played a key role in securing funding for the UK’s National Formulation Centre, and led Pfizer’s efforts in addressing nitrosamine risk across its portfolio. Dr. Coupe earned his B.Pharm. and Ph.D. in drug delivery both from the University of Nottingham.
Dr. Colin Rowlings, SVP of CMC at Actio Biosciences: Dr. Rowlings has led CMC teams across biotech companies including Gossamer Bio, Ardea Biosciences, and in his current position with Actio Biosciences. He has contributed to the development of oral, inhalation, nasal, and parenteral dosage forms, including enabling technologies such as ASDs and modified-release formulations, assisting over 30 biotech companies as an independent consultant. Dr. Rowlings earned his B.Pharm. in pharmacy from the University of Queensland, Australia and Ph.D. in pharmaceutics from the University of Iowa.
Professor Yvonne Perrie, Chair in Drug Delivery at the University of Strathclyde: Professor Perrie is an expert in drug and vaccine delivery systems, with prior academic appointments at Aston University. She has authored over 150 peer-reviewed papers, holds multiple patents, and is a Fellow of several scientific societies including the Royal Society of Chemistry and the Royal Pharmaceutical Society. In 2024, she was appointed a Member of the Order of the British Empire (MBE) in His Majesty the King’s New Year Honours List 2024 for services to pharmaceutical innovation and regulation. Professor Perrie earned her Ph.D. from the University of London.
"The collective experience and insight of the SAB will be invaluable as we continue to expand our technology and service offering.” commented Dr. Andy Lewis, Chief Scientific Officer, Quotient Sciences. “I’m looking forward to working closely with our Scientific Advisory Board members and seeing the positive impact their contributions make to our company’s future.”
About Quotient Sciences
Quotient Sciences is an integrated CRDMO (contract research, development and manufacturing organization) providing services across the entire drug development pathway. Our flagship platform for drug development, Translational Pharmaceutics®, has been trusted for integrated drug product formulation development and manufacturing with clinical testing activities for over 17 years. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. To learn more, visit quotientsciences.com.